Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 8/20 | 0.51 |
| ▸ | FDPS | P14324 | 10/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52495 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL7807607 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL53191 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL54443 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL53735 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL53611 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL52996 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL52879 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL52239 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL53872 | 1.00 | GGPS1 (0.51) | GGPS1FDPSLPAR3SMPD1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4615431-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-09-17 | — | — | EP | claimed |
| EP-4604957-A1 | COMBINATIONS OF A SERD FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | claimed |
| US-20250205233-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-06-26 | — | — | US | claimed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | claimed |
| EP-4519418-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | claimed |
| WO-2006118630-A2 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-11-09 | — | — | WO | claimed |
| US-20050165245-A1 | Phospholipid-analogous compounds | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-07-28 | — | — | US | claimed |
| US-20030083313-A1 | Treatment of breast cancer with a liposome mixture comprising an antineoplastic alkylphospholipid and water- or lipid-soluble antiestrogen agents | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2003-05-01 | — | — | US | claimed |
| EP-1135193-B1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | MAX DELBRUECK CENTRUM (DE) | 2002-10-30 | — | — | EP | claimed |
| EP-1135193-A1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2001-09-26 | — | — | EP | claimed |
| WO-2000033917-A1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2000-06-15 | — | — | WO | claimed |
| EP-0507337-B1 | Novel erucyl, brassidyl and nervonyl derivatives | MAX PLANCK GESELLSCHAFT (DE) | 1996-10-23 | — | — | EP | claimed |
| US-5436234-A | Treatment of protozoal and fungal diseases, autoimmune diseases and bone marrow damage | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG (DE) | 1995-07-25 | — | — | US | claimed |
| EP-0507337-A2 | Novel erucyl, brassidyl and nervonyl derivatives | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-10-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, PI4K2A, PIK3CA | GGPS1 1852/4885FDPS 2820/4885LPAR3 870/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | GGPS1 3741/4885FDPS 4490/4885LPAR3 1082/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | GGPS1 2636/4885FDPS 2709/4885LPAR3 1885/4885 |
| US-20250205233-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | GGPS1 4052/4885FDPS 4278/4885LPAR3 1117/4885 |
| US-20050165245-A1 | Phospholipid-analogous compounds | PHOSPHO1, SGMS1, SGMS2 | GGPS1 120/4885FDPS 358/4885LPAR3 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.